We checked this claim: is it true that
Geron discontinued its Phase 3 trial of imetelstat in myelofibrosis because the drug failed to show an overall survival benefit?
Geron halted the Phase 3 IMpactMF trial on October 28, 2026, after an independent data monitoring committee found imetelstat was unlikely to extend patient survival compared with standard therapy
Geron slumps 15% after ending bone marrow cancer study
Regulators and outside monitors advised that imetelstat would not help myelofibrosis patients live longer than existing care.
In a nutshell
Geron Corporation terminated its late-stage clinical study evaluating its drug imetelstat in patients with myelofibrosis, a severe bone marrow cancer, after outside monitors determined the medicine was not helping patients live longer than standard therapy. The shutdown triggered a 15% plunge in Geron's stock and forced the company to retrench around selling the drug for an already-approved blood disorder while exploring earlier-stage combination treatments.
Highlights
- Independent monitors found imetelstat unlikely to extend survival in myelofibrosis patients compared with existing care.
- Geron terminated the late-stage IMpactMF trial on October 28, 2026.
- Company shares dropped more than 15% immediately following the shutdown announcement.
- The halted clinical trial had enrolled 327 patients across its study sites.
From the Editor’s Diary
When a late-stage therapy fails to prove it can keep cancer patients alive longer than standard treatment, single-drug pipelines face sudden commercial contraction, forcing drugmakers to lean entirely on existing approvals to stay afloat.
Who's involved
Geron Corporation
California biotechnology firm that developed the cancer drug imetelstat
goal → expand Rytelo into myelofibrosis to drive long-term commercial revenue
Independent Data Monitoring Committee (IDMC)
outside medical oversight panel evaluating clinical trial results
goal → protect participant safety and ensure trial validity
Harout Semerjian
Chief Executive Officer and President of Geron
goal → safeguard business value by shifting focus to approved blood disease sales
Joseph E. Eid, MD
Executive Vice President of Research and Chief Medical Officer at Geron
goal → oversee the trial shutdown and analyze clinical patient records
Myelofibrosis Patients
people with advanced blood cancer resistant to standard medicines
goal → find a viable second-line therapy capable of extending life
In short
Geron has lost its primary pipeline expansion path after halting late-stage testing of its flagship drug in a deadly bone marrow cancer. The decision immediately strips the company of a major commercial target, leaving its revenue growth tied to a single previously approved blood disorder.
The company will now pivot its resources toward selling the medicine for its established indication while trying to regroup around early-stage combination testing. That outcome remains uncertain because moving back to earlier-stage testing requires fresh clinical validation and time.
The drug, imetelstat, is an intravenous telomerase inhibitor marketed as Rytelo, which blocks an enzyme that cancer cells rely on to divide. The company had enrolled 327 patients with relapsed or refractory myelofibrosis, a severe bone marrow malignancy where scar tissue impairs normal blood production, who had failed previous treatments. Independent monitors tracking patient progress concluded the medicine was not on track to beat existing therapies at prolonging life, forcing an immediate halt to monotherapy development despite identifying no new safety hazards.
Flagged by: Life & Health Science Barometer · 31 October 2026
How it unfolded
Geron Files Disclosure Halting IMpactMF Study
Geron disclosed in a regulatory filing on October 28, 2026, that it was terminating its late-stage IMpactMF study after an independent committee concluded the drug would not meet its primary goal of prolonging overall survival.
Shares Tumble as Leadership Shifts Commercial Focus
The disclosure triggered an immediate selloff on Wall Street, knocking more than 15% off Geron's share price as financial models stripped out projected earnings from second-line myelofibrosis. Company executives responded by redirecting attention to selling Rytelo for its approved use in lower-risk myelodysplastic syndromes, an abnormal blood-cell condition, while keeping open the possibility of testing the therapy in frontline combination regimens.
Where things stand
The Phase 3 IMpactMF clinical trial is officially closed, ending the single-agent path for imetelstat in advanced myelofibrosis after standard drugs fail. No subsequent trial revisions took place between October 29 and October 31, 2026. The next development depends on detailed analyses of secondary findings, including symptom control and disease progression among the 327 study participants, which Geron plans to present at upcoming scientific gatherings.